Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Amneal Pharmaceuticals (AMRX)

Amneal raises 2025 guidance as Q2 revenue rises 3% to $725 million

Positive Impact 4 of 5 guidance Written later

Amneal Pharmaceuticals reported second-quarter 2025 net revenue of $725 million, up 3% from a year earlier, and GAAP net income attributable to the company of $22 million, up from $6 million. The company raised its full-year 2025 adjusted EBITDA and adjusted diluted EPS guidance, while keeping net revenue guidance unchanged, and completed a debt refinancing that it says extends maturities to 2032.

Key points

  • Q2 2025 net revenue was $725 million, up 3% from $702 million; GAAP diluted EPS was $0.07 versus $0.02, and adjusted diluted EPS was $0.25, up 56%.
  • Adjusted EBITDA was $184 million, up 13% from the second quarter of 2024.
  • 2025 guidance: adjusted EBITDA raised to $665 million-$685 million from $650 million-$675 million; adjusted diluted EPS raised to $0.70-$0.75 from $0.65-$0.70; net revenue unchanged at $3.0 billion-$3.1 billion.
  • On August 1, 2025, the company completed $2.1 billion of new seven-year Term B loans and $600 million of 6.875% senior secured notes due 2032, used to refinance prior debt.

The filing

CompanyAmneal Pharmaceuticals (AMRX)
Form8-K, current report
Filed with the SECAug 5, 2025, 6:15 AM ET
Accession number0001723128-25-000037

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.